ClinicalTrials.gg

Program

romaciclib

Its studies are mostly in Leukemia, Myeloid, Acute · Primary Myelofibrosis, led by Ryvu Therapeutics.

Furthest: phase 2, since Sep 7, 20215 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ryvu Therapeutics52 open or runningphase 2since Sep 7, 2021Sep 7, 2021Dec 2026phase 2 · NCT06987058

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 7, 2021First study: phase 2 study in RecurrenceFirst studyNCT05052255 · 66 enrolled · Poland, Spain
  2. Dec 19, 2023Phase 2 study in Leukemia, Myeloid, AcuteNCT06191263 · 98 planned · France, Italy, Poland and more
  3. Jan 5, 2024Phase 2 study in Leukemia, Myeloid, AcuteNCT06268574 · 62 enrolled · France, Italy, Poland and more
  4. Apr 29, 2024Phase 2 study in Primary MyelofibrosisNCT06397313 · 36 enrolled · Italy, Poland
  5. May 15, 2025Phase 2 study in Leukemia, Myeloid, AcuteNCT06987058 · 14 planned · France, Poland

Ahead

  1. Dec 2026Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT06987058
  2. Aug 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT06191263

TargetBeta

CDK8 →read by rule
“An orally bioavailable inhibitor of cyclin-dependent kinases 8 and 19 (CDK8/19), ”NCIt, by rule

Other programs on CDK8

ProgramCompanyFurthest phaseStudies
SEL-120ruleRyvu Therapeuticsphase 27

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06987058Leukemia, Myeloid, Acute · France, Poland2By invitationDec 202614
NCT06397313Primary Myelofibrosis · Italy, Poland2TerminatedJun 30, 202636
NCT06268574Leukemia, Myeloid, Acute · France, Italy, Poland and more2TerminatedJun 30, 202562
NCT06191263Leukemia, Myeloid, Acute · France, Italy, Poland and more2RecruitingAug 202798
NCT05052255Recurrence · Poland, Spain2TerminatedOct 2, 202566

How it is read

Names in the registry

  • “RVU120”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.